Clinical Report: Prognostic Model Utilizing Inflammatory Biomarkers to Predict Immunotherapy Response in Patients with Recurrent or Metastatic Cervical Cancer

Overview

This study developed an inflammatory biomarker-based prognostic model to predict immunotherapy outcomes in patients with recurrent or metastatic cervical cancer (r/m CC). The model demonstrated strong predictive performance and could guide treatment decision-making.

Background

Cervical cancer (CC) is a significant health burden, with a low 5-year survival rate of 17% in patients with r/m CC. Conventional biomarkers like PD-L1 expression have limitations in predicting immunotherapy efficacy, necessitating the exploration of alternative predictive indicators.

Data Highlights

Key Findings

• The inflammatory biomarker-based model was developed using data from 263 patients with r/m CC.
• Optimal cutoff values for inflammatory markers were established for predicting outcomes.
• The LASSO-Cox model showed strong predictive performance for overall survival (OS) and progression-free survival (PFS).
• Time-dependent ROC curves indicated area under the curve values for OS and PFS in both training and validation cohorts.
• Calibration curves confirmed consistency between predicted and observed survival outcomes.

Clinical Implications

The inflammatory biomarker-based prognostic model can assist clinicians in identifying r/m CC patients who may benefit from anti-PD-1/PD-L1 therapy. This model provides a more dynamic and accessible approach to predicting treatment outcomes compared to traditional biomarkers.

Conclusion

The study presents a reliable inflammatory biomarker-based model for predicting immunotherapy outcomes in r/m CC, enhancing clinical decision-making.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial - ScienceDirect
3. European Commission Approves Cemiplimab for Recurrent/Metastatic Cervical Cancer | CancerNetwork
4. The ASCO Post — New Computational Tool May Predict Immunotherapy Outcomes in Patients With Metastatic Breast Cancer
5. Creation of Clinical Inflammatory Models to Assess Neoadjuvant Chemoradiotherapy Effectiveness and Patient Survival in Locally Advanced Rectal Cancer: A Retrospective Analysis
6. The ASCO Post — Predictive Models for Outcomes With Immune Checkpoint Inhibitor Treatment in Metastatic Melanoma
7. the asco post — Predictive Biomarker Under Study in Colorectal Cancer
8. Cervical Cancer NCCN Clinical Practice Guidelines in Oncology - Version 4.2025 | ICCP Portal
9. FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage III-IVA cervical cancer
10. label
11. 1 Recommendations | Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer | Guidance | NICE
12. Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial - ScienceDirect
13. European Commission Approves Cemiplimab for Recurrent/Metastatic Cervical Cancer | CancerNetwork
14. Low pre-treatment neutrophil-to-lymphocyte ratio predicted a better survival in recurrent/metastatic cervical cancer treated with PD-1/PD-L1 inhibitors | Discover Oncology | Springer Nature Link
15. Systemic immune-inflammatory index for the prediction of the survival in patients with cervical cancer: a meta-analysis - ScienceDirect
16. Evaluating the prognostic relevance of neutrophil-to-lymphocyte ratio in cervical cancer: a systematic review and meta-analysis - PMC
17. Prognostic value of platelet to lymphocyte ratio in patients with cervical cancer: an updated systematic review and meta-analysis | World Journal of Surgical Oncology | Springer Nature Link